Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HEMATOLOGIC RECOVERY AND SURVIVAL OF LYMPHOMA PATIENTS AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION - COMPARISON OF BONE-MARROW AND PERIPHERAL-BLOOD PROGENITOR CELLS
Autore:
BRICE P; MAROLLEAU JP; PAUTIER P; MAKKE J; CAZALS D; DOMBRET H; DAGAY MF; BENBUNAN M; GISSELBRECHT C;
Indirizzi:
HOP ST LOUIS,HDJ HEMATOL,INST HEMATOL,1 AVE CLAUDE VELLEFAUX F-75475 PARIS 10 FRANCE
Titolo Testata:
Leukemia & lymphoma
fascicolo: 5-6, volume: 22, anno: 1996,
pagine: 449 - 456
SICI:
1042-8194(1996)22:5-6<449:HRASOL>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; COLONY-STIMULATING FACTOR; GROWTH-FACTOR; THERAPY; DISEASE; AUTOGRAFTS; ETOPOSIDE; LEUKEMIA; RELAPSE;
Keywords:
BONE MARROW TRANSPLANTATION; LYMPHOMA; PERIPHERAL STEM-CELL; TRANSPLANTATION; HEMATOGIC RECOVERY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
P. Brice et al., "HEMATOLOGIC RECOVERY AND SURVIVAL OF LYMPHOMA PATIENTS AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION - COMPARISON OF BONE-MARROW AND PERIPHERAL-BLOOD PROGENITOR CELLS", Leukemia & lymphoma, 22(5-6), 1996, pp. 449-456

Abstract

Autologous stem-cell transplantation is widely used as part of the treatment of poor prognosis lymphoma patients. Since 1986, peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and/or hematopoietic growth factors have progressively been used instead of autologus bone marrow (BM) cells. Toxicity, engraftment and long-term outcome were compared in a population oi relapsing or refractory lymphoma patients given high-dose therapy. During 1986 to 1993, 150 patients with refractory or relapsed non-Hodgkin's lymphomas (n = 93) or Hodgkin's disease (n = 57) received intensive therapy followed by the reinjection ofBM (r = 72) or PBPC (n = 78). PBPC were collected by aphereses duringthe phase of hematologic recovery after mobilization by chemotherapy alone (n = 36) or associated with GCSF (n = 43). Conditioning regimensincluded chemotherapy alone in 77%, associated with total body irradiation (TBI) in 23%. After stem-cell reinfusion, 55% of the PBPC group received GCSF versus 24% in the BM group. Results show that the mediantime to neutrophil counts >500/mu l and platelets >50,000/mu l was significantly shorter in the PBPC than the BM group, respectively 13 versus 23 days and 18 versus 26 days (P < 0.05). This difference remainedsignificant (P < 0.05) when patients were stratified according to theadministration or not of GCSF after transplantation. PBPC grafting after high-dose therapy was associated with a median reduction of the hospital stay of 10 days. The majority of patients (90%) maintained normal blood counts at 3 months, and no secondary graft failure was observed in either group. The use of TBI in the conditioning regimen was theonly significant factor affecting long-term hematologic recovery. Forrelapsing patients with histologically aggressive lymphomas, overall survival and failure-free survival were similar in both groups. In conclusion, PBPC transplantation is a safe procedure associated with improvement of hematopoietic recovery and a shortened hospital stay.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 03:52:46